Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.

Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.

A statistical analysis of Skyscraper-01’s second interim read is inadvertently posted on a Roche website.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.

After generating unexpectedly positive TIGIT data Roche moves to launch a phase 3 trial.